{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:36:24Z","timestamp":1787312184600,"version":"build-2736575974"},"reference-count":84,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T00:00:00Z","timestamp":1643846400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.jid.2022.01.014","type":"journal-article","created":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T16:42:33Z","timestamp":1646325753000},"page":"1778-1785","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":81,"title":["From Empirical to Pathogenesis-Based Treatments for Psoriasis"],"prefix":"10.1016","volume":"142","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0084-3131","authenticated-orcid":false,"given":"Peter CM.","family":"van de Kerkhof","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2022.01.014_bib1","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1084\/jem.192.5.681","article-title":"Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells","volume":"192","author":"Abrams","year":"2000","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jid.2022.01.014_bib2","doi-asserted-by":"crossref","first-page":"494","DOI":"10.4049\/jimmunol.162.1.494","article-title":"IL-17 is produced by nickel- specific T lymphocytes and regulates ICAM-1 expression and chemokine production in human keratinocytes: synergistic or antagonist effects with IFN-gamma and TNF-alpha","volume":"162","author":"Albanesi","year":"1999","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jid.2022.01.014_bib3","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1001\/jamadermatol.2019.4029","article-title":"Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis","volume":"156","author":"Armstrong","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2022.01.014_bib4","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1517\/13543784.9.1.95","article-title":"The treatment of psoriasis with IL-10: rationale and review of the first clinical trials","volume":"9","author":"Asadullah","year":"2000","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.jid.2022.01.014_bib5","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1046\/j.1523-1747.1999.00749.x","volume":"113","author":"Austin","year":"1999","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2022.01.014_bib6","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/1523-1747.ep12276718","article-title":"Psoriatic epidermal cells demonstrate increased numbers and function of non-Langerhans antigen-presenting cells","volume":"92","author":"Baadsgaard","year":"1989","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2022.01.014_bib7","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMc1811317","article-title":"Inhibition of the interleukin-36 pathway for the treatment of generalized pustular psoriasis","volume":"380","author":"Bachelez","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2022.01.014_bib8","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/j.1365-2133.1984.tb04678.x","article-title":"Epidermal T lymphocytes and HLA-DR expression in psoriasis","volume":"110","author":"Baker","year":"1984","journal-title":"Br J Dermatol"},{"issue":"1 Suppl","key":"10.1016\/j.jid.2022.01.014_bib9","doi-asserted-by":"crossref","first-page":"89S","DOI":"10.1038\/jid.1995.18","article-title":"Intralesional T-lymphocyte activation as a mediator of psoriatic epidermal hyperplasia","volume":"105","author":"Bata-Csorgo","year":"1995","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2022.01.014_bib10","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00281-019-00766-z","article-title":"Resolution of plaque-type psoriasis: what is left behind (and reinitiates the disease)","volume":"41","author":"Benezeder","year":"2019","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.jid.2022.01.014_bib11","doi-asserted-by":"crossref","first-page":"5392","DOI":"10.4049\/jimmunol.0903520","article-title":"Ezrin, maspin, peroxiredoxin 2, and heat shock protein 27: potential targets of a streptococcal-induced autoimmune response in psoriasis","volume":"184","author":"Besgen","year":"2010","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jid.2022.01.014_bib12","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.jaad.2020.10.085","article-title":"Tapinarof in the treatment of psoriasis: a review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor-modulating agent","volume":"84","author":"Bissonnette","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2022.01.014_bib13","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.4049\/jimmunol.174.6.3695","article-title":"IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes","volume":"174","author":"Boniface","year":"2005","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jid.2022.01.014_bib14","doi-asserted-by":"crossref","first-page":"4615","DOI":"10.4049\/jimmunol.178.7.4615","article-title":"Oncostatin M secreted by skin infiltrating T lymphocytes is a potent keratinocyte activator involved in skin inflammation","volume":"178","author":"Boniface","year":"2007","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jid.2022.01.014_bib15","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1365-2133.2005.06538.x","article-title":"Plaque psoriasis vs. atopic dermatitis and lichen planus: a comparison for lesional T-cell subsets, epidermal proliferation and differentiation","volume":"153","author":"Bovenschen","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2022.01.014_bib16","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1038\/jid.2011.139","article-title":"Foxp3+ regulatory T cells of psoriasis patients easily differentiate into IL-17A-producing cells and are found in lesional skin","volume":"131","author":"Bovenschen","year":"2011","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2022.01.014_bib17","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/BF00560390","article-title":"Structural aspects of initial psoriatic lesions","volume":"251","author":"Braun-Falco","year":"1974","journal-title":"Arch Dermatol Forsch"},{"key":"10.1016\/j.jid.2022.01.014_bib18","doi-asserted-by":"crossref","first-page":"6071","DOI":"10.2174\/1381612820666140314145445","article-title":"P4 medicine needs P4 education","volume":"20","author":"Cesario","year":"2014","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.jid.2022.01.014_bib19","doi-asserted-by":"crossref","first-page":"9282","DOI":"10.1073\/pnas.91.20.9282","article-title":"CD8+ T cells in psoriatic lesions preferentially use T-cell receptor V beta 3 and\/or V beta 13.1 genes","volume":"91","author":"Chang","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jid.2022.01.014_bib20","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.4049\/jimmunol.1302313","article-title":"Epidermal Th22 and Tc17 cells form a localized disease memory in clinically healed psoriasis","volume":"192","author":"Cheuk","year":"2014","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jid.2022.01.014_bib21","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1084\/jem.20160258","article-title":"Psoriatic T cells recognize neolipid antigens generated by mast cell phospholipase delivered by exosomes and presented by CD1a","volume":"213","author":"Cheung","year":"2016","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jid.2022.01.014_bib22","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/jid.2010.340","article-title":"Integrative responses to IL-17 and TNF-\u03b1 in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis","volume":"131","author":"Chiricozzi","year":"2011","journal-title":"J\u00a0Invest Dermatol"},{"issue":"Suppl.","key":"10.1016\/j.jid.2022.01.014_bib23","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1007\/BF00585919","article-title":"Contrasting disease patterns in psoriasis and atopic dermatitis","volume":"279","author":"Christophers","year":"1987","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jid.2022.01.014_bib24","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/nm1605","article-title":"Alpha1beta1 integrin is crucial for accumulation of epidermal T cells and the development of psoriasis","volume":"13","author":"Conrad","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.jid.2022.01.014_bib25","doi-asserted-by":"crossref","first-page":"11287","DOI":"10.1073\/pnas.0801631105","article-title":"Diverse cytokine production by NKT cell subsets and identification of an IL-17-producing CD4-NK1.1- NKT cell population","volume":"105","author":"Coquet","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jid.2022.01.014_bib26","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1002\/ski2.29","article-title":"Can atopic dermatitis and psoriasis coexist? A systematic review and meta-analysis","volume":"1","author":"Cunliffe","year":"2021","journal-title":"Skin Health Dis"},{"key":"10.1016\/j.jid.2022.01.014_bib27","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3384","article-title":"Psoriasis and genetics","volume":"100","author":"Dand","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jid.2022.01.014_bib28","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.1093\/hmg\/ddx328","article-title":"Exome-wide association study reveals novel psoriasis susceptibility locus at TNFSF15 and rare protective alleles in genes contributing to type I IFN signalling","volume":"26","author":"Dand","year":"2017","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jid.2022.01.014_bib29","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/BF00370733","article-title":"Reappraisal of in situ immunophenotypic analysis of psoriasis skin: interaction of activated HLA-DR+ immunocompetent cells and endothelial cells is a major feature of psoriatic lesions","volume":"286","author":"de Boer","year":"1994","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jid.2022.01.014_bib30","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.immuni.2014.04.019","article-title":"Activation of the aryl hydrocarbon receptor dampens the severity of inflammatory skin conditions","volume":"40","author":"Di Meglio","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.jid.2022.01.014_bib31","article-title":"T\u00a0helper cell subsets in clinical manifestations of psoriasis","volume":"2016","author":"Diani","year":"2016","journal-title":"J\u00a0Immunol Res"},{"key":"10.1016\/j.jid.2022.01.014_bib32","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1001\/jama.1986.03380220076026","article-title":"Cyclosporine improves psoriasis in a double-blind study","volume":"256","author":"Ellis","year":"1986","journal-title":"JAMA"},{"key":"10.1016\/j.jid.2022.01.014_bib33","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1056\/NEJMoa1104200","article-title":"Mutual antagonism of T cells causing psoriasis and atopic eczema","volume":"365","author":"Eyerich","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2022.01.014_bib34","first-page":"117","article-title":"Update on the treatment of psoriasis and psoriatic arthritis - role of apremilast","volume":"5","author":"Forchhammer","year":"2015","journal-title":"Psoriasis (Auckl)"},{"key":"10.1016\/j.jid.2022.01.014_bib35","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.jid.2016.10.021","article-title":"Induction of alternative proinflammatory cytokines accounts for sustained psoriasiform skin inflammation in IL-17C+IL-6KO mice","volume":"137","author":"Fritz","year":"2017","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2022.01.014_bib36","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/exd.13378","article-title":"Autoantigens ADAMTSL5 and LL-37 are significantly upregulated in active psoriasis and localized with keratinocytes, dendritic cells and other leukocytes","volume":"26","author":"Fuentes-Duculan","year":"2017","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jid.2022.01.014_bib37","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jdermsci.2013.04.028","article-title":"The role of IL-22 and Th22 cells in human skin diseases","volume":"72","author":"Fujita","year":"2013","journal-title":"J\u00a0Dermatol Sci"},{"key":"10.1016\/j.jid.2022.01.014_bib38","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1084\/jem.20090480","article-title":"Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8","volume":"206","author":"Ganguly","year":"2009","journal-title":"J\u00a0Exp Med"},{"issue":"5 Suppl.","key":"10.1016\/j.jid.2022.01.014_bib40","doi-asserted-by":"crossref","first-page":"18S","DOI":"10.1111\/1523-1747.ep12505675","article-title":"Immunologic mechanisms in psoriasis","volume":"95","author":"Gottlieb","year":"1990","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2022.01.014_bib41","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.4049\/jimmunol.175.4.2721","article-title":"TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques","volume":"175","author":"Gottlieb","year":"2005","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jid.2022.01.014_bib42","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1084\/jem.164.4.1013","article-title":"Expression of HLA-DR molecules by keratinocytes, and presence of Langerhans cells in the dermal infiltrate of active psoriatic plaques","volume":"164","author":"Gottlieb","year":"1986","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jid.2022.01.014_bib43","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/nm0595-442","article-title":"Response of psoriasis to a lymphocyte selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis","volume":"1","author":"Gottlieb","year":"1995","journal-title":"Nat Med"},{"key":"10.1016\/j.jid.2022.01.014_bib44","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1136\/bmj.293.6549.731","article-title":"Clearance of psoriasis with low dose cyclosporin","volume":"293","author":"Griffiths","year":"1986","journal-title":"Br Med J (Clin Res Ed)"},{"key":"10.1016\/j.jid.2022.01.014_bib45","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jid.2022.01.014_bib46","doi-asserted-by":"crossref","first-page":"6367","DOI":"10.1073\/pnas.86.16.6367","article-title":"Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes","volume":"86","author":"Grossman","year":"1989","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jid.2022.01.014_bib47","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jaad.2018.01.016","article-title":"Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: a randomized, double-blind, phase 2a trial","volume":"78","author":"Guttman-Yassky","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2022.01.014_bib48","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1038\/jid.2009.65","article-title":"Th17 cytokines stimulate CCL20 expression in keratinocytes in\u00a0vitro and in\u00a0vivo: implications for psoriasis pathogenesis","volume":"129","author":"Harper","year":"2009","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2022.01.014_bib49","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.jaci.2014.09.043","article-title":"IL36RN mutations define a severe autoinflammatory phenotype of generalized pustular psoriasis","volume":"135","author":"Hussain","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2022.01.014_bib50","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/exd.12487","article-title":"Cellular sources of IL-17 in psoriasis: a paradigm shift?","volume":"23","author":"Keijsers","year":"2014","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jid.2022.01.014_bib51","first-page":"4312","article-title":"Selective targeting of T cell subsets: focus on alefacept - a remittive therapy for psoriasis","volume":"4","author":"Krueger","year":"2002","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.jid.2022.01.014_bib52","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jaci.2012.04.024","article-title":"IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis","volume":"130","author":"Krueger","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2022.01.014_bib53","doi-asserted-by":"crossref","first-page":"5621","DOI":"10.1038\/ncomms6621","article-title":"The antimicrobial peptide LL37 is a T cell autoantigen in psoriasis [published correction appears in Nat Commun 2015;6:6595]","volume":"5","author":"Lande","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.jid.2022.01.014_bib54","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/nature06116","article-title":"Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide","volume":"449","author":"Lande","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.jid.2022.01.014_bib55","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa2000073","article-title":"Trial of roflumilast cream for chronic plaque psoriasis","volume":"383","author":"Lebwohl","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2022.01.014_bib56","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1084\/jem.20030451","article-title":"Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris","volume":"199","author":"Lee","year":"2004","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jid.2022.01.014_bib57","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1396-0296.2004.04042.x","article-title":"Efalizumab in the treatment of psoriasis","volume":"17","author":"Leonardi","year":"2004","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jid.2022.01.014_bib58","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1016\/j.jid.2016.06.631","article-title":"HLA-C\u221706:02 allele and response to IL-12\/23 inhibition: results from the ustekinumab phase 3 psoriasis program","volume":"136","author":"Li","year":"2016","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2022.01.014_bib59","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1084\/jem.20061308","article-title":"Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides","volume":"203","author":"Liang","year":"2006","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jid.2022.01.014_bib60","doi-asserted-by":"crossref","first-page":"490","DOI":"10.4049\/jimmunol.1100123","article-title":"Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis","volume":"187","author":"Lin","year":"2011","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jid.2022.01.014_bib61","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/nature05663","article-title":"Pathogenesis and therapy of psoriasis","volume":"445","author":"Lowes","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.jid.2022.01.014_bib85","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/sj.jid.5701213","article-title":"Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells","volume":"128","author":"Lowes","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jid.2022.01.014_bib62","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev-immunol-032713-120225","article-title":"Immunology of psoriasis","volume":"32","author":"Lowes","year":"2014","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jid.2022.01.014_bib63","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1056\/NEJMoa1013068","article-title":"Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis","volume":"365","author":"Marrakchi","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2022.01.014_bib64","doi-asserted-by":"crossref","first-page":"4031","DOI":"10.1172\/JCI93396","article-title":"Clinically resolved psoriatic lesions contain psoriasis-specific IL-17-producing \u03b1\u03b2 T cell clones","volume":"127","author":"Matos","year":"2017","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jid.2022.01.014_bib65","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.4049\/jimmunol.155.8.4078","article-title":"Evidence for an antigen-specific cellular immune response in skin lesions of patients with psoriasis vulgaris","volume":"155","author":"Menssen","year":"1995","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jid.2022.01.014_bib66","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.bbrc.2009.05.140","article-title":"TGF-beta is necessary for induction of IL-23R and Th17 differentiation by IL-6 and IL-23","volume":"386","author":"Morishima","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jid.2022.01.014_bib67","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0002-9440(10)65109-7","article-title":"Injection of pre-psoriatic skin with CD4+ T cells induces psoriasis","volume":"155","author":"Nickoloff","year":"1999","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jid.2022.01.014_bib68","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/0140-6736(91)90465-2","article-title":"CD4 antibody treatment of severe psoriasis","volume":"338","author":"Nicolas","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.jid.2022.01.014_bib69","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1189\/JLB.0109046","article-title":"IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines","volume":"86","author":"Ortega","year":"2009","journal-title":"J\u00a0Leukoc Biol"},{"key":"10.1016\/j.jid.2022.01.014_bib70","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa1806382","article-title":"Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis","volume":"379","author":"Papp","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2022.01.014_bib71","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","article-title":"Apremilast, an oral phosphodiesterase-4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)","volume":"73","author":"Papp","year":"2015","journal-title":"Am Acad Dermatol"},{"key":"10.1016\/j.jid.2022.01.014_bib72","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3389\/fimmu.2020.00242","article-title":"Innate lymphocytes in psoriasis","volume":"11","author":"Polese","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2022.01.014_bib73","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/j.jid.2017.05.023","article-title":"Melanocytes: target cells of an HLA-C\u221706:02-restricted autoimmune response in psoriasis","volume":"137","author":"Prinz","year":"2017","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2022.01.014_bib74","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jaad.2018.10.037","article-title":"Phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of plaque psoriasis","volume":"80","author":"Robbins","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2022.01.014_bib75","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/1523-1747.ep12371752","article-title":"T\u00a0cells involved in psoriasis vulgaris belong to the Th1 subset","volume":"102","author":"Schlaak","year":"1994","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2022.01.014_bib76","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1046\/j.1523-1747.1998.00347.x","article-title":"Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes","volume":"111","author":"Teunissen","year":"1998","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2022.01.014_bib77","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.it.2009.07.008","article-title":"Psoriasis \u2013 as an autoimmune disease caused by molecular mimicry","volume":"30","author":"Valdimarsson","year":"2009","journal-title":"Trends Immunol"},{"key":"10.1016\/j.jid.2022.01.014_bib78","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.4049\/jimmunol.0802999","article-title":"Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23\/IL-17 axis","volume":"182","author":"van der Fits","year":"2009","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jid.2022.01.014_bib79","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/jid.2013.477","article-title":"Characterization of innate lymphoid cells in human skin and blood demonstrates increase of NKp44+ ILC3 in psoriasis","volume":"134","author":"Villanova","year":"2014","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2022.01.014_bib80","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.immuni.2004.07.007","article-title":"IL-22 increases the innate immunity of tissues","volume":"21","author":"Wolk","year":"2004","journal-title":"Immunity"},{"key":"10.1016\/j.jid.2022.01.014_bib81","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1172\/JCI118989","article-title":"Dermal injection of immunocytes induces psoriasis","volume":"98","author":"Wrone-Smith","year":"1996","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jid.2022.01.014_bib82","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1084\/jem.20071094","article-title":"Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses [published correction appears in J Exp Med 2008;205:1941]","volume":"204","author":"Zaba","year":"2007","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jid.2022.01.014_bib83","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.jaci.2009.08.046","article-title":"Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signalling, not immediate response TNF genes","volume":"124","author":"Zaba","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2022.01.014_bib84","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/hmg\/ddab237","article-title":"A\u00a0transcriptome-wide association study identifies novel susceptibility genes for psoriasis","volume":"31","author":"Zhu","year":"2021","journal-title":"Hum Mol Genet"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X22000823?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X22000823?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T21:49:26Z","timestamp":1762206566000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X22000823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":84,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S0022202X22000823"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2022.01.014","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From Empirical to Pathogenesis-Based Treatments for Psoriasis","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2022.01.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}